

**Supplementary material****Efficacy and Safety of *de Novo* and Early Use of Extended-release Tacrolimus in Heart Transplantation****Table 1 of the supplementary material**

Multivariate Model for the Incidence of Acute Allograft Rejection

	Odds ratio	95% confidence interval	<i>P</i>
<i>Study group</i>			
Standard-release tacrolimus	1	-	-
Extended-release tacrolimus	0.99	0.49-2.03	.99
Early conversion	0.83	0.35-1.99	.68
<i>Recipient age</i>	0.99	0.97-1.03	.83
<i>Recipient sex (female)</i>	1.41	0.70-2.86	.34
<i>Pretransplant diabetes</i>	1.45	0.72-3.09	.29
<i>Pretransplant infection</i>	0.94	0.29-3.03	.91
<i>Mechanical circulatory support</i>	1.45	0.63-3.43	.38
<i>Donor age</i>	0.99	0.97-1.02	.53
<i>Donor sex (female)</i>	0.76	0.37-1.58	.46
<i>Donor cause of death</i>			
Head trauma	1	-	-
Stroke	1.45	0.69-3.02	.32
Others	0.74	0.24-2.28	.60

<i>CMV serology mismatch</i>	0.83	0.33-2.09	.69
<i>Induction therapy</i>	1.57	0.65-3.82	.32
<i>Statins</i>	0.88	0.41-1.90	.75

Table 2 of the supplementary material

Multivariate Model for the Incidence of Acute Allograft Rejection

	Odds ratio	95% confidence interval	P
<i>Study group</i>			
Standard-release tacrolimus	1	-	-
Extended-release tacrolimus	1.14	0.63-2.04	.67
Early conversion	1.05	0.53-2.12	.87
<i>Recipient age</i>	1.002	0.98-1.03	.84
<i>Recipient sex (female)</i>	1.79	1.01-3.15	.04
<i>Pretransplant diabetes</i>	1.79	1.003-3.19	.04
<i>Pretransplant infection</i>	1.38	0.51-3.73	.53
<i>Mechanical circulatory support</i>	1.71	0.88-3.34	.11
<i>Donor age</i>	0.99	0.97-1.01	.46
<i>Donor sex (female)</i>	0.75	0.41-1.38	.35
<i>Donor cause of death</i>			
Head trauma	1	-	-
Stroke	1.41	0.80-2.48	.23
Others	0.60	0.26-1.39	.23
CMV serology mismatch	0.72	0.34-1.53	.40
Induction therapy	0.82	0.31-1.18	.69

Statins	1.71	0.62-2.19	.62
Nonroutine endomyocardial biopsy	0.25	0.11-0.55	.001

CMV, cytomegalovirus.

Table 3 of the supplementary material**Multivariate Model for the Incidence of Infection**

	Odds ratio	95% confidence interval	<i>P</i>
<i>Study group</i>			
Standard-release tacrolimus	1	-	-
Extended-release tacrolimus	0.83	0.51-1.34	.44
Early conversion	0.62	0.34-1.13	.12
<i>Recipient age</i>	1.01	0.99-1.03	.45
<i>Recipient sex (female)</i>	1.26	0.78-2.01	.35
<i>Recipient body mass index</i>	1.05	0.99-1.10	.07
<i>Pretransplant diabetes</i>	0.79	0.45-1.38	.41
<i>Pretransplant infection</i>	1.57	0.75-3.26	.23
<i>Mechanical circulatory support</i>	1.08	0.42-2.77	.87
<i>Mechanical ventilation</i>	0.97	0.45-2.09	.94
<i>Pretransplant cardiac surgery</i>	0.66	0.39-1.10	.11
<i>Allocation code</i>			
Elective	1	-	-
Urgency code	1.68	0.98-2.90	.06
Emergency code	1.39	0.56-3.47	.48
<i>CMV serology mismatch</i>	0.88	0.43-1.82	.73

<i>Induction therapy</i>	1.16	0.64-2.09	.62
<i>Statins</i>	0.89	0.51-1.56	.68
<i>Cold ischemia time</i>	1.00	0.99-1.04	.96

CMV, cytomegalovirus.

Table 4 of the supplementary material**Multivariate Model for the Incidence of Cytomegalovirus Infection**

	Odds ratio	95 % confidence interval	<i>P</i>
<i>Study group</i>			
Standard-release tacrolimus	1	-	-
Extended-release tacrolimus	0.77	0.29-2.03	.59
Early conversion	0.56	0.18-1.86	.34
<i>Recipient age</i>	1.00	0.97-1.04	.80
<i>Recipient sex (female)</i>	1.70	0.77-3.76	.19
<i>Pretransplant diabetes</i>	0.41	0.12-1.45	.17
<i>Pretransplant infection</i>	1.24	0.27-5.65	.78
<i>CMV serology mismatch</i>	1.69	0.55-5.21	.37
<i>Anti-CMV prophylaxis</i>	0.96	0.43-2.12	.91
<i>Induction therapy</i>	6.70	0.89-50.5	.06
<i>Number of rejection episodes within 1 year of transplantation</i>	0.96	0.78-1.17	.66

CMV, cytomegalovirus.